Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000313881 | SCV000332322 | likely benign | not specified | 2015-06-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000962335 | SCV001109411 | likely benign | not provided | 2025-01-18 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001002272 | SCV001160150 | likely benign | Retinitis pigmentosa 1 | 2018-08-21 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000962335 | SCV001987835 | uncertain significance | not provided | 2019-04-08 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Reported as likely benign in ClinVar but additional evidence is not available (ClinVar SCV000332322.4; Landrum et al., 2016); Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004955367 | SCV005490639 | uncertain significance | Inborn genetic diseases | 2024-09-26 | criteria provided, single submitter | clinical testing | The c.3132A>C (p.K1044N) alteration is located in exon 4 (coding exon 3) of the RP1 gene. This alteration results from a A to C substitution at nucleotide position 3132, causing the lysine (K) at amino acid position 1044 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |